⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session

Published 27/09/2022, 17:23
© Reuters.  Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
IXIC
-
BLPH
-

Gainers

  • Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares surged 159.9% to $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split.
  • PaxMedica, Inc. (NASDAQ: PXMD) jumped 53.5% to $3.33 as the company issued a corporate update after IPO. The company named Stephen D. Sheldon as CFO.
  • Scienjoy Holding Corporation (NASDAQ: SJ) surged 33.4% to $2.2281 after declining 44% on Monday.
  • InMed Pharmaceuticals Inc. (NASDAQ: INM) gained 28% to $6.54. InMed recently reported a FY22 net loss of $33.17 per share.
  • Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) jumped 24% to $1.2001. Bellerophon announced FDA acceptance of change to ongoing Phase 3 REBUILD study of INOpulse for the treatment of fibrotic interstitial lung disease.
  • FingerMotion, Inc. (NASDAQ: FNGR) gained 23% to $0.9999 after rising around 20% on Monday.
  • Intelligent Living Application Group Inc. (NASDAQ: ILAG) rose 21.6% to $2.48 after gaining over 11% on Monday.
  • Grove Collaborative Holdings, Inc. (NYSE: GROV) shares climbed 21.3% to $3.5901. Grove Collaborative continued retail expansion with entry into thousands of more stores.
  • Unico American Corporation (NASDAQ: UNAM) gained 20.8% to $1.5099.
  • 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 20.3% to $0.2490 after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for Vurolenatide in short bowel syndrome.
  • Milestone Scientific Inc. (NASDAQ: MLSS) gained 20% to $0.8193.
  • Avalon GloboCare Corp. (NASDAQ: AVCO) jumped 19.8% to $0.5271.
  • Pyxis Oncology, Inc. (NASDAQ: PYXS) gained 19.8% to $2.30.
  • Biocept, Inc. (NASDAQ: BIOC) gained 17.1% to $0.9368.
  • Equillium, Inc. (NASDAQ: EQ) jumped 15.5% to $2.23. Equillium announced interim results from the Type B portion of the EQUALISE study evaluating itolizumab in patients with lupus nephritis (LN).
  • Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose 14.1% to $8.67.
  • The Beauty Health Company (NASDAQ: SKIN) gained 12.6% to $11.71 after the company announced a $200 million buyback.
  • Stryve Foods, Inc. (NASDAQ: SNAX) jumped 12% to $0.45.
  • Skillz Inc. (NYSE: SKLZ) jumped 11.9% to $1.0750.
  • Verve Therapeutics, Inc. (NASDAQ: VERV) gained 11.5% to $34.73.
  • BitNile Holdings, Inc. (NYSE: NILE) rose 10.6% to $0.2047.
  • CVR Energy, Inc. (NYSE: CVI) gained 8.2% to $27.65.
  • BIT Mining Limited (NYSE: BTCM) rose 7.7% to $0.28 after declining around 9% on Monday.
  • Novavax, Inc. (NASDAQ: NVAX) gained 7.5% to $20.28. Novavax announced an initial one million doses of Nuvaxovid are available for use in the UK.

Losers

  • FedNat Holding Company (NASDAQ: FNHC) fell 19.9% to $0.18 after dropping over 15% on Monday.
  • Eve Holding, Inc. (NYSE: EVEX) dropped 18% to $10.08. BLADE India signed non-binding order for up to 200 eVTOL vehicles from Eve Air Mobility.
  • Polar Power, Inc. (NASDAQ: POLA) fell 15.2% to $2.68 after gaining around 25% on Monday.
  • Avidity Biosciences, Inc. (NASDAQ: RNA) shares fell 14.9% to $15.95. The FDA has placed a partial clinical hold on new participant enrollment in Avidity Biosciences’ Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).
  • Evaxion Biotech A/S (NASDAQ: EVAX) fell 14.9% to $2.34. Evaxion Biotech recently announced it reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01.
  • FaZe Holdings Inc. (NASDAQ: FAZE) dropped 14.2% to $12.66.
  • Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares fell 14.1% to $6.15. Kiora Pharmaceuticals said its stockholders authorized a reverse stock split of its common stock.
  • SAI.TECH Global Corporation (NASDAQ: SAI) dropped 14.1% to $4.10.
  • Midatech Pharma plc (NASDAQ: MTP) fell 14% to $2.2365.
  • Minerva Surgical, Inc. (NASDAQ: UTRS) dipped 13.8% to $0.7320.
  • Provident Financial (LON:PFG) Services, Inc. (NYSE: PFS) fell 12.5% to $20.27. Provident Financial Services and Lakeland Bancorp to merge in an all-stock transaction.
  • 374Water, Inc. (NASDAQ: SCWO) dropped 12.1% to $3.03.
  • Golden Sun Education Group Limited (NASDAQ: GSUN) fell 11.6% to $36.00.
  • Kronos Worldwide, Inc. (NYSE: KRO) dropped 11.2% to $9.48. Barclays (LON:BARC) maintained Kronos Worldwide with an Underweight and lowered the price target from $15 to $8.
  • Inpixon (NASDAQ: INPX) fell 10.4% to $0.1260. Inpixon shares jumped over 21% on Monday after the company announced it signed a definitive merger agreement with KINS Technology for KINS to acquire Inpixon's enterprise apps business.
  • Ocular Therapeutix, Inc. (NASDAQ: OCUL) dropped 10.5% to $4.7250. Ocular Therapeutix announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases.
  • AMTD Digital Inc. (NYSE: HKD) shares fell 8.9% to $59.22.
  • Troika Media Group, Inc. (NASDAQ: TRKA) shares fell 8.5% to $0.3453 after declining 6% on Monday.
  • HeartCore Enterprises, Inc. (NASDAQ: HTCR) dropped 7.9% to $1.05.
  • Studio City International Holdings Limited (NYSE: MSC) fell 6.9% to $2.28.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.